1. Market Research
  2. > Pharmaceutical Market Trends
  3. > BioNumerik Pharmaceuticals, Inc. - Product Pipeline Review - 2013

BioNumerik Pharmaceuticals, Inc. - Product Pipeline Review - 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 22 pages

BioNumerik Pharmaceuticals, Inc. - Product Pipeline Review - 2013


Summary


Global Market Direct’s pharmaceuticals report, “BioNumerik Pharmaceuticals, Inc. - Product Pipeline Review - 2013” provides data on the BioNumerik Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, BioNumerik Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from BioNumerik Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.


Scope


- BioNumerik Pharmaceuticals, Inc. - Brief BioNumerik Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of BioNumerik Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of BioNumerik Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the BioNumerik Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate BioNumerik Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of BioNumerik Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the BioNumerik Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with BioNumerik Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of BioNumerik Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Table Of Contents

BioNumerik Pharmaceuticals, Inc. - Product Pipeline Review - 2013
Table of Contents 2
List of Tables 3
List of Figures 3
BioNumerik Pharmaceuticals, Inc. Snapshot 4
BioNumerik Pharmaceuticals, Inc. Overview 4
Key Information 4
Key Facts 4
BioNumerik Pharmaceuticals, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
BioNumerik Pharmaceuticals, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
BioNumerik Pharmaceuticals, Inc. - Pipeline Products Glance 9
BioNumerik Pharmaceuticals, Inc. - Late Stage Pipeline 9
Phase III Products/Combination Treatment Modalities 9
BioNumerik Pharmaceuticals, Inc. Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
BioNumerik Pharmaceuticals, Inc. - Drug Profiles 12
cositecan 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
dimesna 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
MDAM 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
BioNumerik Pharmaceuticals, Inc. - Pipeline Analysis 17
BioNumerik Pharmaceuticals, Inc. - Pipeline Products by Therapeutic Class 17
BioNumerik Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 18
BioNumerik Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action 19
BioNumerik Pharmaceuticals, Inc. - Locations And Subsidiaries 20
Head Office 20
Appendix 21
Methodology 21
Coverage 21
Secondary Research 21
Primary Research 21
Expert Panel Validation 21
Contact Us 22
Disclaimer 22

List of Tables


BioNumerik Pharmaceuticals, Inc., Key Information 4
BioNumerik Pharmaceuticals, Inc., Key Facts 4
BioNumerik Pharmaceuticals, Inc. - Pipeline by Indication, 2013 6
BioNumerik Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 7
BioNumerik Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 8
BioNumerik Pharmaceuticals, Inc. - Phase III, 2013 9
BioNumerik Pharmaceuticals, Inc. - Phase II, 2013 10
BioNumerik Pharmaceuticals, Inc. - Phase I, 2013 11
BioNumerik Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 17
BioNumerik Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 18
BioNumerik Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 19

List of Figures


BioNumerik Pharmaceuticals, Inc. - Pipeline by Indication, 2013 6
BioNumerik Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 7
BioNumerik Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 8
BioNumerik Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 17
BioNumerik Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 18
BioNumerik Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 19

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.